EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSELUG00000004621
Gene Symbol: GUCY1A1
3 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSELUG00000012079
Gene Symbol: GUCY1A2
4 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSELUG00000004589
Gene Symbol: GUCY1B1
3 Cross references
211 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSELUG00000013060
Gene Symbol: HSP90AB1
1 Cross references
358 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSELUG00000011559
Gene Symbol: LOC105030681
3 Cross references
317 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSELUG00000033398
Gene Symbol: HMGB1B
1 Cross references
511 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSELUG00000007158
Gene Symbol: HMGB1B
1 Cross references
511 Possible Orthologues:

High Mobility Group Protein 1.2-Like

Ensembl ID : ENSELUG00000034296
Gene Symbol: LOC105030407
2 Cross references
498 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSELUG00000015774
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSELUG00000013591
Gene Symbol: HRH2
3 Cross references
181 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSELUG00000017240
Gene Symbol: HRH2A
1 Cross references
192 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSELUG00000003247
Gene Symbol: LOC105015808
4 Cross references
257 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).